Display options
Cite
Areias J, Calinas F, Porto A, et al. One year of Lamivudine therapy for portuguese patients with chronic hepatitis B. Clin Drug Investig. 2003;23(5):339-46doi: 10.2165/00044011-200323050-00004.
Areias, J., Calinas, F., Porto, A., Carvalho, A., Freitas, D., Macedo, G., Noronha, R., Cotter, J., Meliço-Silvestre, A., Peixe, R., Pratas, J., Barrote, D., Teixeira, R., Augusto, F., Carrilho, I., Campante, F., Velosa, J., Carvalho, L., Duarte, M. A., Guerreiro, H., Pires, C., Silva, A., Cotrim, I., Guedes, F., Tomé, L., Marcelino, M., Gonçalves, C., Ferreira, E., Matos, L., Peixe, P., Esteves, J., Valente, T., Simões, C., Marinho, C., Jasmins, L., Vieira, M. J., Marinho, R., Matos, P., Estevens, J., Carrasquinho, J., Salcedo, G., Parada, P., & Teixeira, C. (2003). One year of Lamivudine therapy for portuguese patients with chronic hepatitis B. Clinical drug investigation, 23(5), 339-46. https://doi.org/10.2165/00044011-200323050-00004
Areias, J, et al. "One year of Lamivudine therapy for portuguese patients with chronic hepatitis B." Clinical drug investigation vol. 23,5 (2003): 339-46. doi: https://doi.org/10.2165/00044011-200323050-00004
Areias J, Calinas F, Porto A, Carvalho A, Freitas D, Macedo G, Noronha R, Cotter J, Meliço-Silvestre A, Peixe R, Pratas J, Barrote D, Teixeira R, Augusto F, Carrilho I, Campante F, Velosa J, Carvalho L, Duarte MA, Guerreiro H, Pires C, Silva A, Cotrim I, Guedes F, Tomé L, Marcelino M, Gonçalves C, Ferreira E, Matos L, Peixe P, Esteves J, Valente T, Simões C, Marinho C, Jasmins L, Vieira MJ, Marinho R, Matos P, Estevens J, Carrasquinho J, Salcedo G, Parada P, Teixeira C. One year of Lamivudine therapy for portuguese patients with chronic hepatitis B. Clin Drug Investig. 2003;23(5):339-46. doi: 10.2165/00044011-200323050-00004. PMID: 17535046.
Copy Download .nbib Format: NLM
Share it on

Clin Drug Investig. 2003;23(5):339-46. doi: 10.2165/00044011-200323050-00004.

One year of Lamivudine therapy for portuguese patients with chronic hepatitis B.

Clinical drug investigation

J Areias, F Calinas, A Porto, A Carvalho, D Freitas, G Macedo, R Noronha, J Cotter, A Meliço-Silvestre, R Peixe, J Pratas, D Barrote, R Teixeira, F Augusto, I Carrilho, F Campante, J Velosa, L Carvalho, M A Duarte, H Guerreiro, C Pires, A Silva, I Cotrim, F Guedes, L Tomé, M Marcelino, C Gonçalves, E Ferreira, L Matos, P Peixe, J Esteves, T Valente, C Simões, C Marinho, L Jasmins, M J Vieira, R Marinho, P Matos, J Estevens, J Carrasquinho, G Salcedo, P Parada, C Teixeira

Affiliations

  1. Hospital Geral de Santo António, Oporto, Portugal.

PMID: 17535046 DOI: 10.2165/00044011-200323050-00004

Abstract

OBJECTIVE: To assess the efficacy of lamivudine treatment on hepatitis B e antigen (HBeAg) and/or hepatitis B surface antigen (HBsAg) seroconversion, on other virological and serological markers of response including hepatitis B virus (HBV) DNA and serum aminotransferases, and the safety of lamivudine treatment in hepatitis B patients.

PATIENTS: This phase III open-label study evaluated the virological and biochemical response to lamivudine in 70 Portuguese patients with HBeAg positive chronic hepatitis B. Patients were treated with lamivudine 100mg once daily for 12 months.

METHODS: Antiviral activity was assessed by measuring alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels at all protocol visits, and hepatitis B serology and HBV DNA were performed at baseline and at month 12 visits. Evaluation of safety and tolerance was based on clinical adverse events and laboratory analyses.

RESULTS: The primary endpoint was virological response at month 12, defined as loss of detectable HBeAg from serum with a reduction of HBV DNA to undetectable levels, and this was observed in 19/69 (27.5%) of patients. Almost half of the patients were HBV DNA negative by this time. Mean ALT values decreased steadily during treatment and by 12 months 61% of patients had values within the normal range. HBeAg seroconversion (HBeAg negative, HBeAb positive) was achieved in 27.9% of patients by 12 months, although all patients remained HBsAg positive.

CONCLUSION: Lamivudine was well tolerated and the incidence of adverse events was similar to those reported in previous studies. Lamivudine treatment resulted in virological and biochemical improvements in HBeAg positive chronic hepatitis B patients, with HBeAg seroconversion in one-third of patients.

References

  1. Hepatology. 1983 Sep-Oct;3(5):656-62 - PubMed
  2. Ann Intern Med. 1993 Aug 15;119(4):312-23 - PubMed
  3. N Engl J Med. 1998 Jul 9;339(2):61-8 - PubMed
  4. N Engl J Med. 1997 Dec 11;337(24):1733-45 - PubMed
  5. Hepatology. 1986 Mar-Apr;6(2):167-72 - PubMed
  6. Gut. 2000 Apr;46(4):562-8 - PubMed
  7. Ann Intern Med. 1991 Apr 15;114(8):629-34 - PubMed
  8. Gastroenterology. 1983 Feb;84(2):216-9 - PubMed
  9. Gastroenterology. 1993 Apr;104(4):1116-21 - PubMed
  10. J Infect Dis. 1986 Oct;154(4):562-9 - PubMed
  11. Ann Intern Med. 1995 May 1;122(9):664-75 - PubMed
  12. N Engl J Med. 1999 Oct 21;341(17):1256-63 - PubMed
  13. Pharmacotherapy. 2002 Jun;22(6):721-37 - PubMed
  14. Gastroenterology. 1984 Feb;86(2):230-5 - PubMed
  15. Gastroenterology. 1992 Nov;103(5):1630-5 - PubMed
  16. N Engl J Med. 2003 Feb 27;348(9):808-16 - PubMed
  17. N Engl J Med. 2003 Feb 27;348(9):800-7 - PubMed
  18. Ann Intern Med. 1981 Jun;94(6):744-8 - PubMed
  19. Gastroenterology. 1987 Jan;92(1):220-5 - PubMed
  20. N Engl J Med. 1990 Aug 2;323(5):295-301 - PubMed
  21. Ann Intern Med. 1991 Jul 15;115(2):113-5 - PubMed
  22. Hepatology. 2001 Jun;33(6):1527-32 - PubMed
  23. Liver. 1993 Feb;13(1):15-9 - PubMed
  24. Gut. 1991 Mar;32(3):294-8 - PubMed
  25. N Engl J Med. 1996 May 30;334(22):1422-7 - PubMed
  26. Ann Intern Med. 1984 Nov;101(5):613-6 - PubMed
  27. Cancer. 1988 May 15;61(10):1942-56 - PubMed
  28. Hepatology. 1991 Dec;14(6):969-74 - PubMed
  29. Gastroenterology. 2000 Jul;119(1):172-80 - PubMed
  30. Hepatology. 1988 May-Jun;8(3):493-6 - PubMed

Publication Types